Compare SBI & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBI | GNTA |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | Italy |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 109.7M | 34.0M |
| IPO Year | N/A | 2021 |
| Metric | SBI | GNTA |
|---|---|---|
| Price | $7.71 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 39.5K | ★ 98.0K |
| Earning Date | 01-01-0001 | 03-30-2026 |
| Dividend Yield | ★ 4.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.96 | $1.28 |
| 52 Week High | $8.00 | $10.00 |
| Indicator | SBI | GNTA |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 36.36 |
| Support Level | $7.74 | $1.28 |
| Resistance Level | $7.87 | $1.68 |
| Average True Range (ATR) | 0.05 | 0.18 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 11.11 | 22.78 |
Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager. The Fund also maintains a dollar-weighted average effective maturity of between three and ten years.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.